Literature DB >> 15311217

Proteomics in pathology research.

Megan S Lim1, Kojo S J Elenitoba-Johnson.   

Abstract

Proteomics is a multifaceted approach to study various aspects of protein expression, post-translational modification, interactions, organization and function at a global level. While DNA constitutes the 'information archive of the genome', it is the proteins that actually serve as the functional effectors of cellular processes. Thus, analysis of protein derangements on a proteome-wide scale will reveal insights into deregulated pathways and networks involved in the pathogenesis of disease. Although the field of proteomics has advanced tremendously in recent years, there are significant technical challenges that pose limitations to the routine application of mass spectrometry to clinical research. Despite these challenges, proteomic studies have yielded unparalleled information and understanding of the cellular biology of diseased states. The application of mass spectrometry to the study of diseases will ultimately lead to identification of biomarkers that are critical for the detection, diagnosis, prognosis and treatment of specific disease entities.

Mesh:

Year:  2004        PMID: 15311217     DOI: 10.1038/labinvest.3700167

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

1.  Clinical proteomics: present and future prospects.

Authors:  Nicole M Verrills
Journal:  Clin Biochem Rev       Date:  2006-05

2.  RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells.

Authors:  Christophe Delfour; Pascal Roger; Caroline Bret; Marie-Laurence Berthe; Philippe Rochaix; Nicolas Kalfa; Pierre Raynaud; Frédéric Bibeau; Thierry Maudelonde; Nathalie Boulle
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

Review 3.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

4.  Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.

Authors:  Christopher J Klein; Julie A Vrana; Jason D Theis; Peter J Dyck; P James B Dyck; Robert J Spinner; Michelle L Mauermann; H Robert Bergen; Steven R Zeldenrust; Ahmet Dogan
Journal:  Arch Neurol       Date:  2010-10-11

5.  Study of the three-way interaction between Trichoderma atroviride, plant and fungal pathogens by using a proteomic approach.

Authors:  Roberta Marra; Patrizia Ambrosino; Virginia Carbone; Francesco Vinale; Sheridan L Woo; Michelina Ruocco; Rosalia Ciliento; Stefania Lanzuise; Simona Ferraioli; Ida Soriente; Sarah Gigante; David Turrà; Vincenzo Fogliano; Felice Scala; Matteo Lorito
Journal:  Curr Genet       Date:  2006-08-29       Impact factor: 3.886

Review 6.  A comprehensive overview of proteomics approach for COVID 19: new perspectives in target therapy strategies.

Authors:  Rashmi Rana; Vaishnavi Rathi; Nirmal Kumar Ganguly
Journal:  J Proteins Proteom       Date:  2020-11-02

Review 7.  Mass Spectrometry Imaging of Fibroblasts: Promise and Challenge.

Authors:  Peggi M Angel; Denys Rujchanarong; Sarah Pippin; Laura Spruill; Richard Drake
Journal:  Expert Rev Proteomics       Date:  2021-07-24       Impact factor: 4.250

8.  Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10.

Authors:  Alberta Lucchese; Abraham Mittelman; Mong-Shang Lin; Darja Kanduc; Animesh A Sinha
Journal:  J Transl Med       Date:  2004-12-11       Impact factor: 5.531

9.  An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays.

Authors:  Yiling Lu; Bryan T Hennessy; Dimitra Tsavachidou; Huifang Guo; Wenbin Liu; Zhenlin Ju; Pheroze Tamboli; Eric Jonasch; Gordon B Mills
Journal:  Proteome Sci       Date:  2012-09-24       Impact factor: 2.480

10.  Identification of serum CCL15 in hepatocellular carcinoma.

Authors:  Y Li; J Wu; W Zhang; N Zhang; H Guo
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.